What is the value of the acquisition?
The acquisition values Penumbra at $14.5 billion.
Yanuki
ARTICLE DETAIL
Boston Scientific to Acquire Penumbra for $14.5 Billion | Ameren Announces Pricing of Senior Notes Due 2036 | AEP Declares Quarterly Dividend Amidst $72 Billion Grid Expansion for AI | FMC Corporation Reports Third Quarter Results | Gemini Announces Launch of Initial Public Offering | Bitcoin Whale Sells $9.5 Billion in Crypto After 14,000,000% Return | MCAN Financial Group Reports Q1 2025 Results: Profit Drop and Increased Credit Loss Provisions | ACON Investments Sells Kept Companies to DFW Capital Partners After Successful Growth Period | Boston Scientific to Acquire Penumbra for $14.5 Billion | Ameren Announces Pricing of Senior Notes Due 2036 | AEP Declares Quarterly Dividend Amidst $72 Billion Grid Expansion for AI | FMC Corporation Reports Third Quarter Results | Gemini Announces Launch of Initial Public Offering | Bitcoin Whale Sells $9.5 Billion in Crypto After 14,000,000% Return | MCAN Financial Group Reports Q1 2025 Results: Profit Drop and Increased Credit Loss Provisions | ACON Investments Sells Kept Companies to DFW Capital Partners After Successful Growth Period
Financial Services & Investing / Acquisitions, Mergers and Takeovers
Boston Scientific to Acquire Penumbra for $14.5 Billion
Boston Scientific (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) have announced a definitive agreement for Boston Scientific to acquire Penumbra in a deal valued at $14.5 billion. This acquisition will expand Boston Scientific's cardiovascular...
Key Insights
- **Acquisition Details:** Boston Scientific will acquire Penumbra for $374 per share, valuing the company at approximately $14.5 billion.
- **Strategic Expansion:** The acquisition allows Boston Scientific to enter fast-growing segments within the vascular space, complementing its existing portfolio.
- **Penumbra's Performance:** Penumbra expects to report approximately $1.4 billion in revenue for 2025, representing growth of 17.3% - 17.5% over the previous year.
- **Financial Impact:** The transaction is expected to be $0.06-0.08 dilutive to adjusted earnings per share for Boston Scientific in the first full year following the close of the acquisition, neutral to slightly accretive in the second year, and more accretive thereafter.
- **Leadership Transition:** Penumbra's chairman and CEO, Adam Elsesser, will join Boston Scientific's board of directors upon closing of the deal.
In-Depth Analysis
The acquisition of Penumbra by Boston Scientific represents a significant strategic move in the medical technology industry. Penumbra's focus on innovative therapies for complex medical conditions, such as stroke and pulmonary embolism, aligns with Boston Scientific's commitment to advancing science for life.
**Key Areas of Expansion:**
- **Mechanical Thrombectomy:** Penumbra's Lightning Bolt® and Lightning Flash® CAVT™ systems will enhance Boston Scientific's capabilities in removing blood clots from arterial, venous, and pulmonary vessels.
- **Neurovascular Solutions:** Penumbra's differentiated solutions for stroke revascularization and neuro embolization will provide Boston Scientific with a stronger presence in the neurovascular market.
- **Vascular Portfolio:** The addition of Penumbra’s minimally invasive peripheral embolization system will enable Boston Scientific to control hemorrhaging and bleeding more effectively.
**Financial and Market Impact:**
The acquisition is expected to be completed in 2026, pending Penumbra's stockholder approval and other customary closing conditions. Boston Scientific plans to finance the cash portion of the transaction through a combination of cash on hand and new debt. While the deal is expected to be dilutive in the short term, it is projected to become accretive in the long term due to the growth and innovation of Penumbra's offerings.
FAQ
What are the key benefits for Boston Scientific?
The acquisition expands Boston Scientific's cardiovascular portfolio and provides entry into the mechanical thrombectomy and neurovascular markets.
When is the deal expected to close?
The transaction is expected to be completed in 2026, subject to customary closing conditions.
Takeaways
- Boston Scientific is set to acquire Penumbra for $14.5 billion, enhancing its cardiovascular offerings.
- The acquisition includes Penumbra's innovative thrombectomy and neurovascular technologies.
- Penumbra expects significant revenue growth in 2025, projecting approximately $1.4 billion.
- The deal is anticipated to be accretive to Boston Scientific's earnings in the long term.
- Penumbra's CEO will join Boston Scientific's board of directors.
Discussion
Do you think this acquisition will drive further innovation in the treatment of vascular diseases? Let us know in the comments!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.